Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Mark W. Weatherall"'
Autor:
Simon Erridge, Ophilia Leung, Carl Holvey, Ross Coomber, Sushil Beri, Shaheen Khan, Mark W. Weatherall, James J. Rucker, Michael W. Platt, Mikael H. Sodergren
Publikováno v:
Neuropsychopharmacology Reports, Vol 43, Iss 4, Pp 616-632 (2023)
Abstract Introduction While there is increasing evidence of the effects of cannabis‐based medicinal products (CBMPs) on health‐related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity of studied CBMPs. Th
Externí odkaz:
https://doaj.org/article/d62ee49e28054088a17fabbb04c94272
Autor:
Kavyesh Vivek, Zekiye Karagozlu, Simon Erridge, Carl Holvey, Ross Coomber, James J. Rucker, Mark W. Weatherall, Mikael H Sodergren
Publikováno v:
Brain and Behavior, Vol 14, Iss 2, Pp n/a-n/a (2024)
Abstract Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia. Methods A case series of UK patients
Externí odkaz:
https://doaj.org/article/a3e581e5239f4578802925ef8044de7a
Autor:
Simon Erridge, Oliver Salazar, Michal Kawka, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Sushil Beri, Jonathan Hoare, Shaheen Khan, Mark W. Weatherall, Michael Platt, James J. Rucker, Mikael H. Sodergren
Publikováno v:
Neuropsychopharmacology Reports, Vol 41, Iss 3, Pp 362-370 (2021)
Abstract Aim Cannabis‐based medicinal products (CBMPs) are prescribed with increased frequency, despite a paucity of high‐quality randomized controlled trials. The aim of this study is to analyze the early outcomes of the first series of patients
Externí odkaz:
https://doaj.org/article/054e64bcc4ca44e28126934b4cf0eba1
Autor:
Simon Erridge, Carl Holvey, Ross Coomber, Jonathan Hoare, Shaheen Khan, Michael W. Platt, James J. Rucker, Mark W. Weatherall, Sushil Beri, Mikael H. Sodergren
Publikováno v:
Neuropediatrics. 54:174-181
Background There is a paucity of high-quality evidence of the efficacy and safety of cannabis-based medicinal products in treatment of treatment-resistant epilepsy (TRE) in children. Methods A case series of children ( Results Thirty-five patients we
Autor:
Fabian Olsson, Simon Erridge, James Tait, Carl Holvey, Ross Coomber, Sushil Beri, Jonathan Hoare, Shaheen Khan, Mark W Weatherall, Michael Platt, James J Rucker, Mikael H Sodergren
BACKGROUND: There is a paucity of high-quality data on patient outcomes and safety after initiating treatment with cannabis-based medicinal products (CBMPs). The aim of this study was to assess the clinical outcomes and safety of CBMPs by analyzing p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07765db45b05527ce35525c672b2ed67
http://hdl.handle.net/10044/1/103614
http://hdl.handle.net/10044/1/103614
Autor:
Lara Bapir, Simon Erridge, Martha Nicholas, Manaswini Pillai, Nishaanth Dalavaye, Carl Holvey, Ross Coomber, Jonathan Hoare, Shaheen Khan, Mark W Weatherall, James J Rucker, Michael Platt, Mikael H Sodergren
INTRODUCTION: There is growing evidence on the efficacy of cannabis-based medicinal products (CBMPs) for chronic pain (CP). Due to the interaction between CP and anxiety, and the potential impact of CBMPs on both anxiety and CP, this article aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adeeb5d0f61ba2e7ff26327dba47e272
Autor:
Mehmet Ergisi, Simon Erridge, Michael Harris, Michal Kawka, Devaki Nimalan, Oliver Salazar, Katerina Loupasaki, Rayyan Ali, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Sushil Beri, Jonathan Hoare, Shaheen A. Khan, Mark W. Weatherall, Michael Platt, James J. Rucker, Mikael H. Sodergren
Introduction: There is a growing body of literature supporting the efficacy of cannabis-based medicinal products (CBMPs). Despite an increase in prescribing globally, there is a paucity of high-quality clinical data on the efficacy of CBMPs for many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a881b8bc6e4d46f908692fd04b286036
http://hdl.handle.net/10044/1/100270
http://hdl.handle.net/10044/1/100270
Autor:
Mark W Weatherall
Publikováno v:
Therapeutic delivery. 12(9)
Ajovy (fremanezumab, Teva Pharmaceuticals, Israel) is a fully humanized monoclonal antibody that selectively binds both isoforms of the calcitonin gene-related peptide. Calcitonin gene-related peptide is a 37-amino acid neuropeptide involved in centr
Autor:
Dipankar Nandi, Mark W Weatherall
Publikováno v:
British Journal of Neurosurgery. 33:608-612
Purpose: Primary headache disorders are common, but many patients are refractory to medical treatment. Percutaneous electrical nerve stimulation (PENS) therapy involves the stimulation of one or mo...
Autor:
David J. Weatherall, Shantha Hettiarachchi, Nizri Hameed, Taraka Pilapitiya, Gihan Weerasinghe, Nancy F. Olivieri, Ishari Silva, Arunasalam Pathmeswaran, Udaya K. Ranawaka, A. Hapangama, K.A. Salvin, Mark W Weatherall, Anuja Premawardhena
Publikováno v:
British journal of haematology. 185(3)
Neurological manifestations are reported only occasionally in patients with thalassaemia and are given much less prominence than the complications related to anaemia and iron overload. White matter changes (WMCs) on magnetic resonance imaging (MRI) i